Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Código da empresaGKOS
Nome da EmpresaGlaukos Corp
Data de listagemJun 25, 2015
CEOBurns (Thomas William)
Número de funcionários995
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço1 Glaukos Way
CidadeALISO VIEJO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92656
Telefone19493679600
Sitehttps://www.glaukos.com
Código da empresaGKOS
Data de listagemJun 25, 2015
CEOBurns (Thomas William)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados